Relation between inhibition of platelet aggregation and clinical outcomes

American Heart Journal

Volumn 136, Issue 4 II SUPPL., 1998, Pages

  Harrington, R A ^a   Kleiman, N S ^a   Granger, C B ^a   Ohman, E M ^a   Berkowitz, S D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; TIROFIBAN; UNCLASSIFIED DRUG;

CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

EID: 0031735461     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1998.v136.93433     Document Type: Article

References (39)

1. Antiplatelet Trialists’ Collaboration Collaborative overview of randomised trials of antiplatelet therapy, II: maintenance of vascular graft or arterial patency by antiplatelet therapy Br Med J 308 1994 159 168
2. J Lefkovits EF Plow EJ Topol Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine N Engl J Med 332 1995 1553 1559
3. JH Alexander RA Harrington Antiplatelet and antithrombin therapies in the acute coronary syndromes Curr Opin Cardiol 12 1997 427 437
4. RA Harrington BG Macik Monitoring the coagulation system after thrombolytic therapy 2nd ed RM Califf DB Mark GS Wagner Acute coronary care 1995 Mosby St Louis 469 480
5. CB Granger J Hirsh RM Califf J Col HD White A Betriu Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial Circulation 93 1996 870 878
6. CB Granger RM Califf F Van de Werf HD White EJ Topol for the GUSTO IIa Investigators Activated partial thromboplastin time and clinical outcome among patients with unstable angina or non-Q-wave MI treated with intravenous heparin [abstract] Circulation 92 suppl I 1996 I.416, I.417
7. EM Hylek SJ Skates MA Sheehan DE Singer An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation N Engl J Med 335 1996 540 546
8. JR O’Brien Platelet aggregation, II: some results from a new method of study J Clin Pathol 15 1962 152
9. EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
10. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
11. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
12. The IMPACT II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II Lancet 349 1997 1422 1428
13. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
14. JJ Ferguson III Meeting highlights: XIXth Congress of the European Society of Cardiology Circulation 96 1997 3818 3821
15. JJ Ferguson Meeting highlights: 46th annual scientific sessions of the American College of Cardiology Circulation 96 1997 367 371
16. HC Tan RA Harrington JE Tcheng Platelet glycoprotein IIb/IIIa integrin blockade in coronary artery disease: current state of the art J Thromb Thrombol 4 1997 431 439
17. JE Tcheng SG Ellis BS George Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody fab 7E3 in high-risk coronary angioplasty Circulation 90 1994 1757 1764
18. JE Tcheng RA Harrington K Kottke-Marchant Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention Circulation 91 1995 2151 2157
19. RA Harrington NS Kleiman K Kottke-Marchant Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention Am J Cardiol 76 1995 1222 1227
20. DJ Kereiakes NS Kleiman J Ambrose Randomized double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty J Am Coll Cardiol 27 1996 536 542
21. P Theroux S Kouz L Roy Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian lamifiban study Circulation 94 1996 899 905
22. GV Born Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 1962 927 933
23. SD Berkowitz AL Frelinger III RS Hillman Progress in point-of-care laboratory testing for assessing platelet function Am Heart J 136 suppl 1998 S51 S64
24. K Watanabe F Ono Current status and problems of platelet function tests Jpn J Clin Pathol 40 1992 507 514
25. DR Phillips W Teng A Arfsten Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1997 1488 1494
26. L Jennings B Tardiff D Phillips R Scarborough M Kitt D Gretler Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q-wave myocardial infarction J Am Coll Cardiol 31 suppl A 1998 93A
27. L Jennings M White Expression of ligand-induced binding sites on glycoprotein IIB/IIIa complexes and the effect of various inhibitors Am Heart J 135 1998 S179 S183
28. EJ Topol Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence Circulation 97 1998 211 218
29. DR Phillips RM Scarborough Clinical pharmacology of eptifibatide Am J Cardiol 80 4A 1997 11B 20B
30. RA Harrington EM Ohman KN Sigmon Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states [abstract] Circulation 92 suppl I 1995 I.488, I.489
31. RC Becker CP Cannon RP Tracy Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction Am Heart J 131 1996 421 433
32. BS Coller Platelets and thrombolytic therapy N Engl J Med 322 1990 33 42
33. FV Aguirre EJ Topol JJ Ferguson Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention Circulation 91 1995 2882 2890
34. C Simpfendorfer K Kottke-Marchant M Lowrie First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions Circulation 96 1997 76 81
35. CP Cannon K Ault J Mitchell CH McCabe E Braunwald P-selectin in patients post acute coronary syndromes treated with sibrafiban, an oral IIb/IIIa antagonist: results from TIMI 12 [abstract] Circulation 96 1997 I-169
36. DJ Kereiakes JP Runyon NS Kleiman Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention Circulation 94 1996 906 910
37. EJ Topol RM Califf F Van de Werf for the PARAGON Investigators International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina Circulation 97 1998 2386 2395
38. MA Mascelli S Worley NJ Veriabo Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy Circulation 96 1997 3860 3866
39. BS Coller Monitoring platelet GP IIb/IIIa antagonist therapy Circulation 97 1998 5 9